305 - Nanoparticle platform for combination therapy of metastatic prostate cancer
Rakesh K Pathak, email@example.com, Sean Marrache, Shanta Dhar. Department of Chemistry, University of Georgia, Athens, GA 30605, United States
Castration-Resistant Prostate cancer (CRPC) is one of the most prevalent and deadly forms of cancer affecting men in the United States. Currently, chemotherapy is the only form of cancer therapy that has shown to improve the survival of those with CRPC. However, chemotherapeutic agents do not help to relieve many of the symptoms related with CRPC, such as chronic inflammation and bone metastases. Nanotechnology has recently emerged as a promising method for the delivery and tumor accumulation of multiple drugs with high efficiency. FDA approved polymeric nanoparticles (NPs), such as those composed of poly(lactide-co-glycolide) (PLGA) and poly(ethyleneglycol) (PEG), have shown exceptional ability to enter tumor tissues through the enhanced permeability and retention effect (EPR) and release therapeutics in a controlled fashion. Here, we present a controlled-release, highly functionalized NP platform with the capabilities to deliver synergistic combination of chemotherapeutics, anti-inflammatory agents, and bone resorption inhibitors for the treatment of CRPC.
Wednesday, April 10, 2013 07:00 PM
General Poster Session (07:00 PM - 10:00 PM)
Location: Morial Convention Center
Room: Hall A